So you now also know exactly what data Novartis were privy to as well ? That's funny ..... you just make up anything to support your narrative by the looks - Novartis partnership was based upon Remestemcel-L for COVID-19 ARDS but do now try and relate this Novartis partnership to Rexlemestrocel-L and CHF if it makes you feel better ....
So you now also know exactly what data Novartis were privy to as...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.04 |
Change
-0.023(2.11%) |
Mkt cap ! $1.190B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.08 | $1.04 | $3.642M | 3.469M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 93717 | $1.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.05 | 228727 | 23 |
View Market Depth
| Last trade - 12.46pm 13/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.04 |
Change
-0.023 ( 2.49 %) |
||||
| Open | High | Low | Volume | ||
| $1.07 | $1.08 | $1.04 | 654373 | ||
| Last updated 13.02pm 13/05/2024 ? | |||||
| MSB (ASX) Chart |